HROW
Price
$40.03
Change
+$2.11 (+5.56%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
1.4B
31 days until earnings call
OGI
Price
$1.81
Change
-$0.07 (-3.70%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
253.81M
Interact to see
Advertisement

HROW vs OGI

Header iconHROW vs OGI Comparison
Open Charts HROW vs OGIBanner chart's image
Harrow
Price$40.03
Change+$2.11 (+5.56%)
Volume$9.76K
Capitalization1.4B
Organigram Global
Price$1.81
Change-$0.07 (-3.70%)
Volume$7.99K
Capitalization253.81M
HROW vs OGI Comparison Chart in %
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HROW vs. OGI commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a Hold and OGI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (HROW: $37.92 vs. OGI: $1.89)
Brand notoriety: HROW and OGI are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HROW: 79% vs. OGI: 70%
Market capitalization -- HROW: $1.48B vs. OGI: $243.29M
HROW [@Pharmaceuticals: Generic] is valued at $1.48B. OGI’s [@Pharmaceuticals: Generic] market capitalization is $243.29M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HROW’s FA Score shows that 1 FA rating(s) are green whileOGI’s FA Score has 1 green FA rating(s).

  • HROW’s FA Score: 1 green, 4 red.
  • OGI’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than OGI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HROW’s TA Score shows that 5 TA indicator(s) are bullish while OGI’s TA Score has 3 bullish TA indicator(s).

  • HROW’s TA Score: 5 bullish, 5 bearish.
  • OGI’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, HROW is a better buy in the short-term than OGI.

Price Growth

HROW (@Pharmaceuticals: Generic) experienced а -6.53% price change this week, while OGI (@Pharmaceuticals: Generic) price change was -6.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.01%. For the same industry, the average monthly price growth was +4.92%, and the average quarterly price growth was +52.54%.

Reported Earning Dates

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.01% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($1.4B) has a higher market cap than OGI($254M). OGI YTD gains are higher at: 17.391 vs. HROW (13.025). HROW has higher annual earnings (EBITDA): 32.1M vs. OGI (-959K). HROW has more cash in the bank: 53M vs. OGI (36.8M). OGI has less debt than HROW: OGI (9.15M) vs HROW (231M). HROW (228M) and OGI (224M) have equivalent revenues.
HROWOGIHROW / OGI
Capitalization1.4B254M552%
EBITDA32.1M-959K-3,347%
Gain YTD13.02517.39175%
P/E RatioN/A221.23-
Revenue228M224M102%
Total Cash53M36.8M144%
Total Debt231M9.15M2,525%
FUNDAMENTALS RATINGS
HROW vs OGI: Fundamental Ratings
HROW
OGI
OUTLOOK RATING
1..100
7282
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9190
P/E GROWTH RATING
1..100
91
SEASONALITY SCORE
1..100
8513

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HROW's Valuation (82) in the Pharmaceuticals Other industry is in the same range as OGI (87) in the null industry. This means that HROW’s stock grew similarly to OGI’s over the last 12 months.

HROW's Profit vs Risk Rating (47) in the Pharmaceuticals Other industry is somewhat better than the same rating for OGI (100) in the null industry. This means that HROW’s stock grew somewhat faster than OGI’s over the last 12 months.

HROW's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as OGI (100) in the null industry. This means that HROW’s stock grew similarly to OGI’s over the last 12 months.

OGI's Price Growth Rating (90) in the null industry is in the same range as HROW (91) in the Pharmaceuticals Other industry. This means that OGI’s stock grew similarly to HROW’s over the last 12 months.

OGI's P/E Growth Rating (1) in the null industry is in the same range as HROW (9) in the Pharmaceuticals Other industry. This means that OGI’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HROWOGI
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 18 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 16 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CRLVX11.420.01
+0.09%
Catholic Rspnsbl Invstmnts Intl Eq Inv
FEQIX83.59N/A
N/A
Fidelity Equity-Income
MUHLX74.21-0.12
-0.16%
Muhlenkamp
SFMIX43.43-0.32
-0.73%
American Beacon Stephens Mid-Cap Gr R5
WESWX11.36-0.12
-1.05%
TETON Westwood Equity AAA

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with OGI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-3.85%
OGI - HROW
34%
Loosely correlated
-3.57%
AMRX - HROW
32%
Poorly correlated
+0.92%
TKNO - HROW
32%
Poorly correlated
-2.41%
ELAN - HROW
30%
Poorly correlated
+0.05%
AMPH - HROW
29%
Poorly correlated
+0.35%
More

OGI and

Correlation & Price change

A.I.dvisor indicates that over the last year, OGI has been closely correlated with SNDL. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if OGI jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGI
1D Price
Change %
OGI100%
-3.57%
SNDL - OGI
67%
Closely correlated
-4.03%
ACB - OGI
65%
Loosely correlated
-6.04%
TLRY - OGI
64%
Loosely correlated
-8.33%
CGC - OGI
62%
Loosely correlated
-7.53%
CRON - OGI
61%
Loosely correlated
-3.88%
More